25 September 2023: Neko Pharma is coming to BioJapan
Neko Pharma will participate in Japan Healthcare Venture Summit 2023 to be held in Pacifico Yokohama, Japan, from October 11 to 13, 2023. Please visit our booth V-10. We are looking forward to meeting you to discuss future opportunities with our KazanbodyTM technology.
For more information on this event, please visit
https://mediso.mhlw.go.jp/jhvs2023/en/index.html
31 January 2023: First patent issued on KazanbodyTM core technology
The first patent covering the KazanbodyTM core technology has been issued by the USPTO (Patent No. US 11,566,346 B2).
15 December 2022: KazanbodyTM exhibits low immunogenicity ex vivo.
The KazanbodyTM scaffold was found to have low immunogenicity in a time course T-cell proliferation assay using 50 donors of diverse HLA allotypes. The proliferation responses induced in response to the KazanbodyTM scaffold (4%) were similar to the low immunogenicity control Herceptin® (6%) showing a low risk of immunogenicity for the KazanbodyTM scaffold.